A new analysis of the latest type of cholesterol-lowering drugs finds that prices would have to drop by more than two-thirds — to about $4,200 a year — for the medicines to be cost effective.

The findings were made after assessing discounted prices and results of a recent clinical trial that studied cardiovascular outcomes for one of the two available medicines, which are known as PCSK9 inhibitors. One drug is sold by Amgen (AMGN), while the other is marketed jointly by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN). The analysis was published in the Journal of the American Medical Association.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ed, the best and most relevant argument for competition would be the statins. For example sales peaked at $10.8 billion for Lipitor in 2007 vs $5.2 billion for Zocor. The difference was two fold: 1) The superior Pfizer marketing machine, perhaps leading to 2) perceived better efficacy of lipitor

    Their are two complementary scenarios possible with Repatha and Praluent 1) the “win-lose” outcome with as per above, or 2) the two companies won’t throw huge marketing budgets at the products, and in such case there will literally not a dime’s worth of difference in price between them.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy